Buonarati M, Jones A D, Buckpitt A
Department of Pharmacology and Toxicology, School of Veterinary Medicine, University of California, Davis 95616.
Drug Metab Dispos. 1990 Mar-Apr;18(2):183-9.
We have examined the fate of glutathione conjugates derived from naphthalene metabolism at various dose levels (5-80 mg/kg) in an effort to explore the potential use of urinary mercapturic acids as biomarkers of exposure to naphthalene and as indicators of the activity and stereoselectivity of cytochrome P-450-dependent naphthalene epoxidation. This approach extends previous studies which demonstrated a high degree of stereoselectivity in the formation of (+)-1R,2S-naphthalene oxide from naphthalene in target tissue microsomes (mouse lung), but not in microsomal preparations isolated from nontarget tissues such as mouse liver. To validate the use of mercapturic acids as indicators of epoxide formation in vivo, individual naphthalene oxide glutathione adduct isomers were administered iv to mice, and urinary metabolites were identified and quantified. Mercapturates accounted for 69-75% of the administered dose in the 8-hr urines of animals treated with trans-1-(S)-hydroxy-2-(S)-glutathionyl-1,2-dihydronaphthalene (adduct 1) and 76-84% for trans-1-(R)-hydroxy-2-(R)-glutathionyl-1,2-dihydronaphthalene (adduct 2). Only 39-57% of the dose of trans-1-(R)-glutathionyl-2-(R)-hydroxy-1,2-dihydronaphthalene (adduct 3) administered to mice was excreted as the mercapturic acid derivative; however, two additional metabolites were detected which were not present in the urine of animals treated with adducts 1 or 2. The first metabolite, accounting for 2-4% of the dose of adduct 3, was not identified. The second metabolite, isolated by HPLC and identified by mass spectrometry as (hydroxy-1,2-dihydronaphthalenylthio)pyruvic acid, accounted for 14-25% of the administered dose of adduct 3.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了不同剂量水平(5 - 80毫克/千克)下萘代谢产生的谷胱甘肽结合物的去向,以探索尿中硫醚氨酸作为萘暴露生物标志物以及细胞色素P - 450依赖性萘环氧化活性和立体选择性指标的潜在用途。这种方法扩展了先前的研究,先前研究表明在靶组织微粒体(小鼠肺)中由萘形成(+)-1R,2S - 萘氧化物具有高度立体选择性,但在从非靶组织如小鼠肝脏分离的微粒体制剂中则没有。为了验证硫醚氨酸作为体内环氧化物形成指标的用途,将单个萘氧化物谷胱甘肽加合物异构体静脉注射给小鼠,并对尿代谢物进行鉴定和定量。在用反式-1 - (S)-羟基-2 - (S)-谷胱甘肽基-1,2 - 二氢萘(加合物1)处理的动物的8小时尿液中,硫醚氨酸占给药剂量的69 - 75%,在用反式-1 - (R)-羟基-2 - (R)-谷胱甘肽基-1,2 - 二氢萘(加合物2)处理的动物中占76 - 84%。给小鼠注射的反式-1 - (R)-谷胱甘肽基-2 - (R)-羟基-1,2 - 二氢萘(加合物3)剂量中只有39 - 57%以硫醚氨酸衍生物形式排泄;然而,检测到另外两种代谢物,它们不存在于用加合物1或2处理的动物尿液中。第一种代谢物占加合物3剂量的2 - 4%,未被鉴定。第二种代谢物通过高效液相色谱分离并通过质谱鉴定为(羟基-1,2 - 二氢萘硫基)丙酮酸占加合物3给药剂量的14 - 25%。(摘要截断于250字)